Exicure Inc (XCUR)
NASDAQ:XCUR
Want to see XCUR full AI Analyst Report?
XCUR Stock Chart & Stats
$5.93
-$0.13(-1.36%)
At close: 4:00 PM EST
$5.93
-$0.13(-1.36%)
Day’s Range― - ―
52-Week Range$3.10 - $11.86
Previous CloseN/A
Volume39.94K
Average Volume (3M)23.77K
Market Cap
$22.12M
Enterprise Value$18.55M
Total Cash (Recent Filing)$3.75M
Total Debt (Recent Filing)$176.00K
Price to Earnings (P/E)―
Beta0.91
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding6,373,915
10 Day Avg. Volume33,737
30 Day Avg. Volume23,774
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)8.69
Price to Sales (P/S)0.00
P/FCF Ratio-3.99
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-118.14
Enterprise Value/Ebitda-1.92
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetEliminating all debt materially reduces fixed financing obligations and interest risk, improving financial flexibility. Over the medium term this structural change gives management more optionality to fund R&D, pursue partnerships, or withstand cash volatility without immediate debt servicing constraints.
Phase 2 Milestone With GPCRCompleting a Phase 2 study and submitting the clinical study report to the FDA is a durable R&D advance that de-risks that program and locks in commercial economics (milestone payment and adjusted sublicensing share). It strengthens long-term pipeline value and future licensing or development options.
Strengthened Governance And OperationsAdding an experienced COO and a new director on the audit committee, alongside governance reforms, improves operational execution and oversight capacity. Stronger governance and seasoned operational leadership reduce structural execution and compliance risk over the next several quarters.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow, worsening in 2025, indicates the company cannot self-fund operations. Over the medium term this creates structural dependence on external financing or asset monetization, increasing dilution risk and constraining R&D and commercialization pacing.
Recurring Losses & Volatile RevenueConsistent annual net losses combined with highly unstable revenue demonstrate the company lacks a durable commercial revenue base. This undermines margin predictability and makes multi-period planning and sustained investment in the pipeline more uncertain without new predictable revenue sources.
Thin And Shrinking Equity BaseA materially reduced equity cushion reflects accumulated deficits and limits the firm's ability to absorb further losses or secure favorable financing. Structurally, thin equity increases vulnerability to dilution and reduces negotiating leverage with partners and lenders during critical development stages.
Exicure News
XCUR FAQ
What was Exicure Inc’s price range in the past 12 months?
Exicure Inc lowest stock price was $3.10 and its highest was $11.86 in the past 12 months.
What is Exicure Inc’s market cap?
Exicure Inc’s market cap is $22.12M.
When is Exicure Inc’s upcoming earnings report date?
Exicure Inc’s upcoming earnings report date is May 20, 2026 which is in 23 days.
How were Exicure Inc’s earnings last quarter?
Exicure Inc released its earnings results on Mar 25, 2026. The company reported -$0.455 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.455.
Is Exicure Inc overvalued?
According to Wall Street analysts Exicure Inc’s price is currently Overvalued.
Does Exicure Inc pay dividends?
Exicure Inc does not currently pay dividends.
What is Exicure Inc’s EPS estimate?
Exicure Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Exicure Inc have?
Exicure Inc has 6,373,915 shares outstanding.
What happened to Exicure Inc’s price movement after its last earnings report?
Exicure Inc reported an EPS of -$0.455 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Exicure Inc?
Currently, no hedge funds are holding shares in XCUR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Exicure Inc
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Technical Analysis
Ownership Overview
25.09% Insiders
0.84% Mutual Funds
0.88% Other Institutional Investors
72.52% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---